Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study.

IF 5.1 2区 医学 Q1 RHEUMATOLOGY
Antonio Manzo, Emanuele Bozzalla Cassione, Carlomaurizio Montecucco, Garifallia Sakellariou, Blerina Xoxi, Terenzj Luvaro, Ylenia Sammali, Ludovico De Stefano, Claudia Alpini, Catherine Klersy, Serena Bugatti
{"title":"Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study.","authors":"Antonio Manzo, Emanuele Bozzalla Cassione, Carlomaurizio Montecucco, Garifallia Sakellariou, Blerina Xoxi, Terenzj Luvaro, Ylenia Sammali, Ludovico De Stefano, Claudia Alpini, Catherine Klersy, Serena Bugatti","doi":"10.1136/rmdopen-2024-005079","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To delineate, within the framework of current clinical practice and criteria, the sustainability of first-line immuno-suppressive treatment discontinuation in rheumatoid arthritis (RA) and the impact of residual disease in remission on long-term drug-free (DF) outcomes.</p><p><strong>Methods: </strong>RA patients, referring to the Pavia early arthritis clinic (EAC) between 2009 and 2021 and achieving remission after Disease Activity Score-driven methotrexate (MTX) monotherapy, were recruited. Eligible patients underwent DF follow-up at 3-month intervals over 5 years after MTX discontinuation. Pre-selected clinical, serological and ultrasound (US) exposure variables at MTX withdrawal were analysed using multivariable Cox regression to predict time-to-flare.</p><p><strong>Results: </strong>Of 761 EAC patients with RA, 132 started DF follow-up (person-months: 3678). 62 experienced a flare after a median (range) of 9 (3-60) months, resulting in a progressive decline in flare-free survival throughout the observation period. Whole-cohort multivariate Cox regression identified anti-citrullinated protein antibody (ACPA) positivity (HR: 4.20, 95% CI 2.37 to 7.44) and hands' joints with grey scale (US-GS) alterations (GS>1; HR: 2.18, 95% CI 1.20 to 3.93) as independent predictors. ACPA-positive patients in Simplified Disease Activity Index (SDAI) remission displayed a flare-free survival estimate at 5 years of 6.4% (95% CI 1.2 to 35.7) versus 78.2% (95% CI 67.4 to 90.8) for ACPA-negative patients in SDAI remission without residual US-GS alteration in hands' joints (n=59); the latter group showing no evidence of radiographic progression and functional deterioration.</p><p><strong>Conclusions: </strong>Long-term DF remission is attainable in a niche subset of ACPA-negative RA. Examining clinical and subclinical residual synovial abnormalities during remission allows for effective preemptive identification of this subset in real life.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 1","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781140/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"RMD Open","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/rmdopen-2024-005079","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To delineate, within the framework of current clinical practice and criteria, the sustainability of first-line immuno-suppressive treatment discontinuation in rheumatoid arthritis (RA) and the impact of residual disease in remission on long-term drug-free (DF) outcomes.

Methods: RA patients, referring to the Pavia early arthritis clinic (EAC) between 2009 and 2021 and achieving remission after Disease Activity Score-driven methotrexate (MTX) monotherapy, were recruited. Eligible patients underwent DF follow-up at 3-month intervals over 5 years after MTX discontinuation. Pre-selected clinical, serological and ultrasound (US) exposure variables at MTX withdrawal were analysed using multivariable Cox regression to predict time-to-flare.

Results: Of 761 EAC patients with RA, 132 started DF follow-up (person-months: 3678). 62 experienced a flare after a median (range) of 9 (3-60) months, resulting in a progressive decline in flare-free survival throughout the observation period. Whole-cohort multivariate Cox regression identified anti-citrullinated protein antibody (ACPA) positivity (HR: 4.20, 95% CI 2.37 to 7.44) and hands' joints with grey scale (US-GS) alterations (GS>1; HR: 2.18, 95% CI 1.20 to 3.93) as independent predictors. ACPA-positive patients in Simplified Disease Activity Index (SDAI) remission displayed a flare-free survival estimate at 5 years of 6.4% (95% CI 1.2 to 35.7) versus 78.2% (95% CI 67.4 to 90.8) for ACPA-negative patients in SDAI remission without residual US-GS alteration in hands' joints (n=59); the latter group showing no evidence of radiographic progression and functional deterioration.

Conclusions: Long-term DF remission is attainable in a niche subset of ACPA-negative RA. Examining clinical and subclinical residual synovial abnormalities during remission allows for effective preemptive identification of this subset in real life.

通过联合临床和超声评估残留疾病预测acpa阳性和acpa阴性类风湿关节炎的长期无药结局:一项5年前瞻性研究
目的:在目前的临床实践和标准框架内,描述类风湿性关节炎(RA)一线免疫抑制治疗停药的可持续性以及缓解期残留疾病对长期无药(DF)结局的影响。方法:招募2009年至2021年间在Pavia早期关节炎诊所(EAC)就诊并在疾病活动评分驱动的甲氨蝶呤(MTX)单药治疗后获得缓解的RA患者。符合条件的患者在MTX停药后5年内每隔3个月接受DF随访。使用多变量Cox回归分析MTX停药时预选的临床、血清学和超声(US)暴露变量,以预测发作时间。结果:761例EAC RA患者中,132例开始DF随访(人月:3678)。62例患者在中位(范围)9个月(3-60个月)后出现耀斑,导致整个观察期间无耀斑生存期逐渐下降。全队列多因素Cox回归鉴定抗瓜氨酸蛋白抗体(ACPA)阳性(HR: 4.20, 95% CI 2.37 ~ 7.44)和手部关节灰度(US-GS)改变(GS bbb1;HR: 2.18, 95% CI 1.20 ~ 3.93)作为独立预测因子。简化疾病活动指数(SDAI)缓解期acpa阳性患者的5年无发作生存率为6.4% (95% CI 1.2 - 35.7),而手部关节无残留US-GS改变的SDAI缓解期acpa阴性患者的5年无发作生存率为78.2% (95% CI 67.4 - 90.8) (n=59);后一组无影像学进展和功能恶化的证据。结论:在acpa阴性RA的小众亚群中,长期DF缓解是可以实现的。在缓解期间检查临床和亚临床残留滑膜异常,可以在现实生活中有效地先发制人地识别这一亚群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
RMD Open
RMD Open RHEUMATOLOGY-
CiteScore
7.30
自引率
6.50%
发文量
205
审稿时长
14 weeks
期刊介绍: RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信